# Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

> **NCT07048886** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Center for Sight Las Vegas** · enrollment: 68 (estimated)

## Conditions studied

- Primary Open Angle Glaucoma

## Interventions

- **DRUG:** Rocklatan (netarsudil 0.02% and latanoprost 0.005%)
- **DRUG:** Systane

## Key facts

- **NCT ID:** NCT07048886
- **Lead sponsor:** Center for Sight Las Vegas
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07048886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07048886, "Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07048886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*